home / stock / aps:cc / aps:cc news

APS:CC News and Press, Aptose Biosciences Inc. From 08/14/25

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APS:CC
Market: TSXC
Website: aptose.com
Menu
APS:CC APS:CC Quote APS:CC Short APS:CC News APS:CC Articles APS:CC Message Board
Get APS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APS:CC - Expected earnings - Aptose Biosciences Inc.

Aptose Biosciences Inc. (APS:CA) is expected to report for Q2 2025
APS:CC - Aptose Reports Second Quarter 2025 Results

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee ( CSRC) Recommends Tuspetinib Dose Escalation to 160 mg Dose Hanmi...

APS:CC - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations No dose reductions...

APS:CC - Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF; OTCQB: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat pat...
APS:CC - Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid l...

APS:CC - Aptose Upgraded to Trade on OTCQB Market

SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patie...

APS:CC - Aptose Announces Deferral of Interest Payment

SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid l...
APS:CC - Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid l...

APS:CC - Aptose Provides Corporate Updates

Announces short-term cash advance SAN DIEGO and TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced today that the Company has ...

APS:CC - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3-wildtype, safely achieved complete remissions and MRD negativity ...
Previous 10 Next 10